ARCH Venture Partners XII, LLC - 10 Jun 2024 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Reporting relationship: 10%+ Owner
Issuer ticker: RAPP
Reported as of: 10 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2024, 19:46:32 UTC
Prior SEC filing: 06 Jun 2024
Next SEC filing: 30 Jan 2025
Source filing: View source filing
Reporting owner signature: ARCH Venture Fund XII, L.P. By: ARCH Venture Partners XII, L.P., its General Partner By: ARCH Venture Partners XII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact

Key filing fact

ARCH Venture Partners XII, LLC filed Form 4 for Rapport Therapeutics, Inc. (RAPP) on 10 Jun 2024.

Key facts

This page summarizes ARCH Venture Partners XII, LLC's Form 4 filing for Rapport Therapeutics, Inc. (RAPP).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Jun 2024, 19:46.

Change

Previous filing in this sequence was filed on 06 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RAPP transaction

Common Stock

Conversion of derivative security

Transaction value: $0
Shares: +3,728,738
Change %
Price: $0.000000
Shares after: 3,728,738
Date: 10 Jun 2024
Ownership: By ARCH Venture Fund XII, L.P.
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RAPP transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -20,000,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 10 Jun 2024
Ownership: By ARCH Venture Fund XII, L.P.
Underlying class: Common Stock
Underlying amount: 2,336,000
Exercise price
Footnotes: F1, F2

RAPP transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -11,924,138
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 10 Jun 2024
Ownership: By ARCH Venture Fund XII, L.P.
Underlying class: Common Stock
Underlying amount: 1,392,738
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Upon the closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Preferred Stock had no expiration date.

Footnote F2

Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.